FDA to import versions of common cancer drug to alleviate shortage

05 Jun 2023
endpts.com
The FDA is hoping its latest solution will stave off the continued shortage of cisplatin, a key drug used in treating several types of cancer. Beginning tomorrow , orders can be placed for cisplatin shipments from China-based Qilu Pharmaceutical Co., which worked in coordination with the FDA and generic drugmaker Apotex to try to help with the shortage. FDA Commissioner Robert Califf said on Friday that the agency began the process to import certain “foreign-approved versions” of cisplatin from FDA-registered facilities. According to a document, Qilu has started the “temporary importation” of cisplatin into the US even though the injection from QiluQilu is marketed and manufactured in China and is not approved by the FDA.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.